rs11037909 — EXT2

EXT2 rs11037909 — A Bone Gene's Quiet Role in Blood Sugar

EXT2 is best known as the gene mutated in hereditary multiple exostoses — a skeletal disorder causing abnormal cartilage-capped bony outgrowths. But in 2007, a French genome-wide association study surprised researchers by linking the EXT2-ALX4 chromosomal region to type 2 diabetes susceptibility¹¹ type 2 diabetes susceptibility
Sladek et al. Nature 2007. The rs11037909 variant sits within an intron of EXT2 and has since been confirmed in a meta-analysis across nearly 20,000 individuals, with carriers of the C allele showing a small but consistent elevation in diabetes risk.

The Mechanism

EXT2 encodes one of two glycosyltransferases (EXT1 and EXT2 form a heterodimer) that build heparan sulfate chains on proteoglycans — sugar-protein complexes embedded in the cell surface and extracellular matrix. Heparan sulfate (HS) is far more than structural scaffolding: it acts as a co-receptor that concentrates and presents growth factors, including the insulin-like signals and FGF family members that regulate adipocyte differentiation and pancreatic beta-cell function.

Mouse studies using conditional Ext1 knockouts — which share the same biosynthetic pathway as EXT2 — show that reducing HS production in visceral white adipose tissue disrupts the BMP4-FGF1 signaling axis, producing smaller lipid droplets, impaired adipocyte differentiation, and reduced insulin-dependent phosphorylation of downstream substrates²² smaller lipid droplets, impaired adipocyte differentiation, and reduced insulin-dependent phosphorylation of downstream substrates
Matsuzawa et al. J Biol Chem 2021, culminating in whole-body insulin resistance and glucose intolerance.

In pancreatic islets, HS produced by the related EXTL3 enzyme is required for postnatal beta-cell proliferation and glucose-stimulated insulin secretion³³ postnatal beta-cell proliferation and glucose-stimulated insulin secretion
Takahashi et al. 2009. Reduced HS in the islet microenvironment impairs the growth factor signaling needed for beta-cell maturation. Because EXT2 operates in the same biosynthetic pathway, intronic variants that alter its expression level are plausible modulators of islet HS abundance.

rs11037909 is an intronic variant — it does not change the EXT2 protein directly. The most likely mechanism is a regulatory effect on EXT2 expression, reducing heparan sulfate chain production enough to subtly impair the growth factor co-receptor function in metabolically active tissues.

The Evidence

The EXT2 locus first emerged from a GWAS of a French cohort, where the EXT2-ALX4 region reached genome-wide significance for type 2 diabetes. A 2013 meta-analysis by Liu et al. in Human Genetics⁴⁴ Liu et al. in Human Genetics pooled 9,224 cases and 10,484 controls and found all three EXT2 SNPs — rs3740878, rs11037909, and rs1113132 — significantly associated with T2D, with odds ratios of approximately 1.07 and a meta-analysis p-value of 0.008 for rs11037909. The OR is modest but consistent across studies that replicated the finding.

Population specificity is notable. The association has been confirmed in European- and Han Chinese-predominant meta-analyses but not replicated in a Burkina Faso cohort (OR 0.89, p=0.74) or in a large Chinese Han replication (OR 1.003). The C allele frequency itself varies substantially — ~16% in Africans versus ~44% in East Asians — which affects statistical power and the applicability of effect estimates across populations.

The evidence level is rated moderate: the locus has been replicated in large meta-analyses with a plausible biological mechanism, but the modest OR and population-specific non-replication mean this variant does not yet meet the bar for clinical use.

Practical Actions

The actionable implication of EXT2 rs11037909 centers on protecting insulin sensitivity through dietary strategies that specifically support insulin receptor signaling — not generic lifestyle advice, but approaches matched to the mechanistic pathway this variant affects.

Inositol (as myo-inositol) is a mediator of post-receptor insulin signaling that has been shown in randomized trials to improve insulin sensitivity in individuals with insulin resistance phenotypes. Low-glycemic-index carbohydrate patterns directly reduce the insulin secretory burden on beta-cells, complementing a genetic background where beta-cell HS function may be subtly impaired. Fasting glucose monitoring provides an early window into developing insulin resistance before clinical thresholds are reached.

Interactions

rs11037909 is in partial linkage disequilibrium with rs3740878 and rs1113132, two other intronic EXT2 variants at the same locus. All three tag the same disease-associated haplotype, so carrying the C allele at rs11037909 and the risk alleles at the other two simultaneously indicates deeper penetrance of the EXT2 haplotype effect. The locus also sits near ALX4, a homeobox transcription factor involved in skeletal and possibly pancreatic development; whether ALX4 contributes to the T2D signal independently of EXT2 has not been resolved.

Metabolically, rs11037909 acts additively with other insulin resistance variants such as ENPP1 K121Q (rs1044498) and TCF7L2 rs7903146. Individuals carrying risk alleles at multiple insulin resistance loci should consider earlier and more frequent fasting glucose monitoring.